Cambridge Institute for Medical Research

Our strategy

CIMR is a unique partnership between basic and clinical research, aiming to understand the cellular basis of disease. Our goal is to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Research advances

Chris Gawden-Bone in the Griffiths lab has revealed in Immunity that PIP5 Kinases Regulate Membrane Phosphoinositide and Actin Composition for Targeted Granule Secretion by Cytotoxic Lymphocytes

Research Advances

Sung Min Son in the Rubinsztein group has reported in Cell Metabolism that in some cells, mTOR complex 1 can be activated by leucine via its metabolite acetyl-CoA.

Research advances

The Rubinsztein group report in Nature Communications that inhibition of cellular recycling through autophagy is an important consequence of contact inhibition.

Research advances

Arianne Richard in the Griffiths (CIMR) and Marioni (CRUK Cambridge institute) labs has reported in Nature Immunology that the killing capacity of cytotoxic T cells is independent of initial ligand stimulation strength.

Research advances

The Larrieu (CIMR) and Jackson groups (Gurdon Institute) reveal in Science Signalling that the transportin-1 nuclear import pathway is an essential target of NAT10 acetyltransferase in progeria and ageing.

Research advances

In Cell Host and Microbe, the Weekes lab have taken a multiplexed proteomics approach to determine which of >10,000 host proteins are degraded during infection by human cytomegalovirus (HCMV), and identify a DNA helicase as a novel anti-viral restriction factor.